Curevac B.V. Stock Price, News & Analysis

CureVac N.V. (NASDAQ:CVAC) will report third quarter and first nine months 2022 financial results on November 16, 2022. A conference call will occur at 3 p.m. CET / 9 a.m. ET, allowing investors and stakeholders access to important business updates. CureVac is focused on developing mRNA-based therapies and is engaged in collaborations for vaccines against infectious diseases, including COVID-19. The company's technology aims to instruct the body to produce proteins that combat various diseases. More details are available on their website.

CureVac N.V. (Nasdaq: CVAC) reported its Q2 2022 financial results, revealing revenues of €20.1 million, a 10% decline year-over-year. Cash reserves stood at €573.6 million, down from €811.5 million as of December 2021. The company initiated Phase 1 trials for its modified COVID-19 vaccine candidate CV0501 targeting the Omicron variant and for the modified influenza vaccine FLU SV mRNA, developed in partnership with GSK. Additionally, CureVac acquired Frame Cancer Therapeutics to bolster its oncology strategy.

CureVac has initiated a Phase 1 clinical study for its modified COVID-19 mRNA vaccine candidate, CV0501, which targets the Omicron variant. This study aims to evaluate the safety and immunogenicity of CV0501 as a booster for previously vaccinated individuals. Conducted across clinical sites in the U.S., UK, Australia, and the Philippines, it plans to enroll up to 180 participants. This milestone underscores CureVac's commitment to advancing its second-generation vaccine technology in collaboration with GSK.

CureVac N.V. (Nasdaq:CVAC) announced that all proposals were approved during its annual general meeting, including the re-appointments and appointments of key supervisory and managing board members. Notable appointments include Craig Tooman, Dr. Debra Barker, and Dr. Klaus Schollmeier as supervisory board members, and Dr. Franz-Werner Haas and Dr. Malte Greune as managing directors. A detailed table of the voting results is expected soon. CureVac specializes in mRNA technology and collaborates with GSK on vaccine development.

CureVac N.V. (NASDAQ: CVAC) has acquired Frame Cancer Therapeutics for €32 million to enhance its oncology strategy. This acquisition will leverage Frame's advanced bioinformatics platform to identify unique neoantigens, potentially leading to innovative cancer vaccines. The acquisition involves a 50% upfront payment in CureVac shares, with additional payments tied to project milestones. The combined expertise is expected to accelerate the development of personalized and off-the-shelf cancer vaccines, strengthening CureVac's position in the oncology market.

CureVac N.V. (NASDAQ:CVAC) announced the appointment of Myriam Mendila as Chief Development Officer, effective February 1, 2023, succeeding Klaus Edvardsen, who will leave the company on June 30, 2022. Mendila brings over 20 years of experience in product development and oncology. Until her start date, Ulrike Gnad-Vogt will serve as interim CDO. CureVac expresses gratitude towards Edvardsen for his contributions, particularly in expanding their pipeline. The company continues to focus on advancing its mRNA technology for various medical applications.

CureVac is enhancing its oncology initiatives through a partnership with myNEO to develop novel mRNA cancer vaccines. This collaboration aims to identify specific tumor antigens that can trigger robust immune responses using myNEO's advanced AI and bioinformatics platform. The agreement focuses on selecting the most promising antigens for clinical testing, leveraging myNEO's genomic data and CureVac's mRNA technology. Both companies aim to build a strong oncology pipeline, expanding beyond existing prophylactic vaccine efforts.

CureVac N.V. (Nasdaq:CVAC) reported significant advancements in its vaccine development, including second-generation candidates for COVID-19 and influenza now in Phase 1 trials. The company is positioned to receive a €10 million milestone payment from GSK for starting its influenza clinical trial. CureVac's cash position is €658.2 million, down from €811.5 million, primarily due to wind-down costs of the CVnCoV vaccine program. Revenues surged 144% to €24.4 million, mainly attributed to collaborations with GSK, while operating loss decreased from €115.8 million to €15.3 million.

CureVac announced its fourth-quarter and full-year 2021 financial results, highlighting a strong cash position of €811.5 million. The company initiated several clinical studies for its second-generation mRNA vaccines targeting COVID-19 and influenza, collaborating with GSK. The CV2CoV candidate is in Phase 1 trials, with promising results from a bivalent vaccine approach. Revenues surged to €103 million, up 111%, driven by GSK collaborations. However, operating losses increased to €412.3 million.